Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOSTER-ITP study of fostamatinib in immune thrombocytopenia
jRCTs031250344Recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fostamatinib in immune thrombocytopenia (ITP), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Platelet response during weeks 16 to 24. Started Apr 2026; status: recruiting.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCTs031250344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250344.